*(K) Korean Session
more
12:10-12:30 | Optimizing Risk Reduction Strategies in Patients with Diabetes and Atherosclerotic Cardiovascular Disease Robert S. Rosenson (The Mount Sinai Hospital in New York, USA) | Abstract |
12:30-12:50 | The Evidence of Using Metformin as a Treatment for Patients with Type 2 Diabetes Hye Soon Kim (Keimyung University, Korea) | Abstract |
more
12:10-12:40 | The Additional Benefits of Anagliptin Beyond Glycemic Control Jun Hwa Hong (Eulji University, Korea) | Abstract |
more
12:10-12:40 | Additional Benefits of Rosuvastatin/Ezetimibe Combination Therapy Yong-ho Lee (Yonsei University, Korea) | Abstract |
more
12:10-12:30 | Advantages of Rosuvastatin and Ezetimibe Combination Treatment Moo-Yong Rhee (Dongguk University, Korea) | Abstract |
12:30-12:50 | Evidence-Based Approach for Ideal Hypertension Management Soon Jun Hong (Korea University, Korea) |
more
12:10-12:30 | See the Unseen in Recent Cardiorenal Outcome Trials of T2DM Treatments Soo Lim (Seoul National University, Korea) | Abstract |
12:30-12:50 | Treatment Approach for Type 2 Diabetes Considering the Stable Glycemic Control So Hun Kim (Inha University, Korea) | Abstract |
more
12:10-12:50 | Current and Future Lipid Treatment through Recent Key Outcomes Anselm K. Gitt (Ludwigshafen University, Germany) | Abstract |
12:50-13:10 | Discussion |
more
12:10-12:30 | The Impact of Empagliflozin beyond Glucose Control : from Mechanism to Outcome Stefano Del Prato (University of Pisa, Italy) | |
12:30-12:50 | Comprehensive Data from Empagliflozin : How These Results Translate into Routine Clinical Practice? Kausik Ray (Imperial College London, UK) | Abstract |
more
12:10-12:40 | Recent Updates in Hypertension Goals: What Does The Physician Need to Know? Sanjay Rajagopalan (Case Western Reserve University, USA) | Abstract |